Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-11-03 |
Curetis (Germany) |
$110 Million (€100 million) |
private placement |
Baillie Gifford (UK) Chartwave Limited (UK) Coppel family (Mexico) Elma Investments (USA) Sigma Group (USA - NJ) |
Cancer - Oncology - Immunological diseases - Infectious diseases |
Private placement |
2015-11-02 |
SEPCELL consortium [Tigenix (Belgium) CHU de Limoges (France) Cliniques Universitaires Saint-Luc (Belgium) Hospital Clínico San Carlos of the Servicio Madrileño de Salud in Madrid (Spain) Academic Medical Center of the University of Amsterdam (The Netherlands)] |
€5.4 million |
grant |
European Commission’s Horizon 2020 programme |
Infectious diseases |
Grant |
2015-11-02 |
Hercules Pharmaceuticals (The Netherlands) |
€ 3,5 million |
grant |
European Eurostars Programme (EU) |
Cancer - Oncology |
Grant |
2015-10-29 |
InteRNA Technologies (The Netherlands) |
$ 10.5 million |
series A financing round |
INKEF Capital (The Netherlands) Aglaia Oncology Fund II (The Netherlands) |
Cancer - Oncology |
Series A financing round |
2015-10-27 |
Oryzon Genomics (Spain) |
$19 million |
private placement |
Bank Solventis (UK) Catalan Institut of Finances (ICF) (Spain) Joseph Fernandez (USA) |
Cancer - Oncology - Neurodegenerative diseases |
Private placement |
2015-10-21 |
Cortendo (Sweden)now Strongbridge Biopharma (Ireland) |
$25 million |
IPO |
|
|
IPO |
2015-10-20 |
Noxxon Pharma (Germany) |
|
IPO |
|
Cancer - Oncology |
IPO |
2015-10-16 |
Basilea Pharmaceutica (Switzerland) |
|
IPO |
|
Infectious diseases - Rare diseases |
IPO |
2015-10-15 |
AB Science (France) |
€ 50 million |
loan |
Crédit Agricole Corporate and Investment Bank (France) |
Rare diseases - Cancer - Oncology |
Establishment of a new subsidiary in the EU |
2015-10-15 |
Keryx Pharmaceuticals (USA - MA) |
$125 million |
private placement |
|
|
Private placement |
2015-10-14 |
Minoryx Therapeutics (Spain) |
€19.4 million ($21.7 million) |
series A financing round |
Ysios Capital (Spain) Kurma Partners (France) Roche Venture Fund (Switzerland) Idinvest Partners (France) Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) |
Rare diseases |
Series A financing round |
2015-10-14 |
Affimed (Germany) |
$21.8 million (€ 19.2 million) |
private placement |
undisclosed existing shareholder |
Cancer - Oncology |
Private placement |
2015-10-13 |
Audentes Therapeutics (USA - CA) |
$65 million |
series C financing round |
Sofinnova Ventures (USA - CA) Redmile Group (USA - CA) RA Capital Management (USA - MA) funds and accounts advised by T. Rowe Price Associates (USA - MD), Rock Springs Capital Management (USA - MD) Cormorant Asset Management (USA - MA) Cowen Private Investments (USA - NY) Foresite Capital (USA - NY) OrbiMed (USA - NY) 5AM Ventures (USA - CA) Versant Ventures (USA - CA) Deerfield Management Company (USA - NY) Venrock (USA - CA) |
Rare diseases - Genetic diseases |
Series C financing round |
2015-10-13 |
Prima Biomed (Australia) |
€1 million |
private placement |
Nyenburgh Investment Partners (NYIP) (The Netherlands) |
Cancer - Oncology |
Private placement |
2015-10-12 |
Medgenics (USA - Israel) |
$46 million |
private placement |
|
Rare diseases |
Private placement |
2015-10-12 |
Gamida Cell (Israel) |
$15 million |
private placement |
Novartis (Switzerland) |
|
Private placement |
2015-10-12 |
Sucampo Pharmaceuticals (USA - MA) |
$250 million |
loan |
|
Gastrointestinal diseases Immunological diseases Ophtalmological diseases Cancer - Oncology |
Loan |
2015-10-09 |
Sarepta Therapeutics (USA - MA) |
$127 Million |
IPO |
|
Rare diseases - Genetic diseases - Neuromuscular diseases |
IPO |
2015-10-02 |
Galapagos (Belgium) |
€1.2 million |
capital increase |
|
|
Capital increase |
2015-10-01 |
Immune Pharmaceuticals (USA - MA, Israel) |
$21.5 million |
loan |
Discover Growth Fund (Cayman Islands) Hercules Technology Growth Capital (USA - CA) |
|
Loan |